Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use metoprolol succinate extended-release tablets USP safely and effectively. See full prescribing information for metoprolol succinate extended release tablets USP. Metoprolol succinate extended-release tablets USP for Oral Use Initial U.S. Approval: 1992
Medication labelWhy this: Advisory · dailymed-prescription
Metoprolol succinate extended-release tablets USP are indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents [see Dosage and Administration (2) ]. Metoprolol succinate extended-release tablets USP are indicated in the long-term treatment of angina pectoris, to reduce angina attacks and to improve exercise tolerance. Metoprolol succinate extended-release tablets USP are indicated for the treatment of stable, symptomatic (NYHA Class II or III) heart failure of ischemic, hypertensive, or cardiomyopathic origin. It was studied in patients already receiving ACE inhibitors, diuretics, and, in the majority of cases, digitalis. In this population, metoprolol succinate extended-release tablets decreased the rate of mortality plus hospitalization, largely through a reduction in cardiovascular mortality and hospitalizations for heart failure.
- generic_name
- metoprolol succinate
- product_names
- Metoprolol Succinate
- ndc
- 21695-950, 62037-831, 21695-950-30, 21695-950-90
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en